Reduced Use of Contrast Agents

REDUCE is a prospective neuroimaging multi-vendor study to investigate if MRI diagnostics with half-dose Dotarem is feasible wihout compromising on patient safety and diagnostic accuracy. REDUCE starts in early 2024 and is funded until 2026. The envisaged sample size is 412 for 4 pathologies (brain metastasis, primary brain tumor, MS, and spine imaging).

REDUCE is an MRI study to find out if MRI can find sickness as good as normally if only half of the contrast agent is injected. Patients with multiple sclerosis, brain cancer and spine problems who get gadolinium-based contrast agents can enroll.